Please login to the form below

Not currently logged in
Email:
Password:

Pfizer’s Elizabeth Barrett joins Novartis as its oncology head

She succeeds Bruno Strigini who retires

Elizabeth BarrettNovartis has appointed Elizabeth Barrett to head up its oncology franchise based at the group’s headquarters in Switzerland.

Barrett, who succeeds Bruno Strigini, has held numerous leadership positions in the pharmaceutical industry as well as in the commercial sector.

She most recently served Pfizer, leading its oncology business but has held several roles with the pharma giant including president, Europe, president North America, speciality care and US president of oncology.

She said: “I feel honoured to join Novartis. It is key to me to contribute to transformative advancements in oncology, and to serve in a highly impactful leadership role to this end.”

Prior to her time with Pfizer, Barrett held roles with Cephalon and Johnson & Johnson.

Vas Narasimhan, chief executive officer at Novartis, said: “Liz is a highly accomplished and recognised oncology and people leader with an impressive record of building successful business organisations in the US.

“She has been instrumental in creating new commercial models, driving innovation in close partnership with research and development and leveraging business development opportunities.

“Her long-time commercial pharma industry experience, marketing skills and perspectives make Liz a great fit to further develop our oncology business.”

12th January 2018

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Six Degrees Medical Consulting

Partnering with top global pharmaceutical companies, we push the boundaries to create meaningful, impactful and lasting learning opportunities. We leverage...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics